REGiMMUNE Limited and Kiji Therapeutics Officially End Potential Merger
Taipei, 27 March 2025 – REGiMMUNE Limited, a biotech company [...]
REGiMMUNE and Kiji Therapeutics Announce Intention to merge
The intended merger will create a pan-global Treg specialist to [...]
REGiMMUNE Featured in “China Times”
TAIPEI, June 4, 2024 – REGiMMUNE Limited is pleased to [...]
REGiMMUNE Welcomes Steve Yang as Chief Operating Officer
TAIPEI, May 6, 2024 – REGiMMUNE Limited, a clinical-stage biopharmaceutical [...]
REGiMMUNE Announces the Poster Presentation at the AACR 2024 Annual Meeting for RGI-2001 Phase 2b latest analyses.
TAIPEI, April 11, 2024 – REGiMMUNE Limited, a clinical-stage biopharmaceutical [...]
Tandem 2024: REGiMMUNE’s RGI-2001 Demonstrates Higher acute GFS without Increased Relapse from the Phase 2b Study
TAIPEI, February 22, 2024 – REGiMMUNE Limited, a clinical-stage biopharmaceutical [...]
REGiMMUNE to Present Results from the Phase 2b Study of RGI-2001 at the 2024 Tandem Meeting
TAIPEI, December 28, 2023 – REGiMMUNE Limited, a clinical-stage biopharmaceutical [...]
REGiMMUNE Signed Underwriting Contract with HuaNan Securities
Taipei, July 6, 2023 – REGiMMUNE Limited (REGiMMUNE), a biotech [...]
REGiMMUNE Licenses The Rights to Develop and Commercialize RGI-2001 To San Fu Biotech in Major Asian Countries
Taipei, March 29, 2023 – REGiMMUNE Limited (REGiMMUNE), a biotech [...]
REGiMMUNE Presented Positive Results of RGI-2001 in the Reduction of Acute GvHD from Phase 2b Study at the 2022 ASH annual meeting
RGI-2001 was well tolerated and associated with a meaningful reduction [...]